tle3b Antibody

What is TLE3 and what are its primary functions in cellular biology?

TLE3 (Transducin-like enhancer protein 3), also known as Enhancer of split groucho-like protein 3 (ESG3), functions as a transcriptional corepressor that interacts with multiple transcription factors. It plays a significant role in inhibiting transcriptional activation mediated by CTNNB1 and TCF family members in the Wnt signaling pathway . The functional effects of full-length TLE family members can be modulated through association with dominant-negative AES (by similarity) . TLE3 belongs to a family of proteins that have been implicated in tumorigenesis and classification of certain cancer types, particularly sarcomas . Understanding its regulatory role in gene expression is critical for researchers investigating developmental processes and cancer biology.

What experimental applications are TLE3 antibodies validated for?

TLE3 antibodies, such as the mouse monoclonal antibody ab213596, have been validated for multiple research applications:

The antibody has been specifically tested with human samples and has been cited in multiple published studies . When selecting a TLE3 antibody for your research, consider the specific application requirements and validate the antibody's performance in your experimental system.

What is the optimal protocol for immunohistochemical detection of TLE3?

For immunohistochemical detection of TLE3, the following methodological approach is recommended:

• Tissue preparation: Use formalin-fixed, paraffin-embedded tissue sections.

• Antigen retrieval: This step is crucial for optimal staining results.

• Antibody application: Apply primary TLE3 antibody (such as polyclonal affinity-purified antibody) at a 1:200 dilution.

• Secondary antibody: Apply appropriate secondary antibody for 1 hour.

• Visualization: Use a detection system such as the DakoCytomation Envision staining kit according to manufacturer's instructions.

• Scoring: A case is typically considered positive if greater than 30% of tumor cell nuclei show staining, regardless of intensity .

TLE3 staining patterns typically show nuclear localization with variable intensity across different samples. There is often a clear delineation between sporadic nuclear staining and near-homogenous staining of all nuclei . Control tissues with expected positive and negative results should be included in each staining run to validate the procedure.

How can I validate the specificity of a TLE3 antibody for my research?

Validating the specificity of a TLE3 antibody requires a multi-faceted approach:

• Positive and negative controls: Include tissues or cell lines known to express or not express TLE3.

• Western blot validation: Confirm the antibody detects a band at the expected molecular weight of 83 kDa .

• Immunogen verification: Check that the antibody was raised against an appropriate immunogen. For example, ab213596 was developed using a recombinant fragment protein within human TLE3 amino acids 150-250 .

• Antibody titration: Perform dilution series to determine optimal antibody concentration.

• Cross-reactivity assessment: Verify specificity by testing against related proteins or in knockout/knockdown models if available.

• Staining pattern analysis: Confirm nuclear localization consistent with TLE3's function as a transcriptional corepressor.

Researchers should document these validation steps thoroughly before proceeding with experimental applications to ensure reliable and reproducible results.

What considerations are important when using TLE3 antibody for prognostic biomarker studies?

When employing TLE3 antibody for prognostic biomarker studies, researchers should address several methodological considerations:

Biomarker studies should follow REMARK (REporting recommendations for tumor MARKer prognostic studies) guidelines to ensure methodological rigor and reproducibility.

How does TLE3 expression correlate with response to taxane therapy in breast cancer?

TLE3 has emerged as a candidate biomarker for predicting response to taxane therapy in breast cancer through systematic biomarker screening efforts. Research findings indicate:

• Initial discovery: In a cohort of 411 patients, TLE3 protein expression was associated with lower risk of recurrence in patients treated with cytotoxic chemotherapy (Hazard Ratio = 0.5) .

• Triple-negative validation: To confirm TLE3 was not merely a surrogate for estrogen receptor or HER2 expression, validation studies were conducted in triple-negative breast cancer cohorts .

• Treatment specificity: TLE3 staining showed an association with improved disease-free interval specifically in taxane-treated patients across independent cohorts .

• Biological plausibility: While the exact mechanism remains under investigation, TLE3's role as a transcriptional corepressor may influence cellular pathways relevant to taxane sensitivity.

These findings suggest TLE3 could potentially serve as a predictive biomarker for selecting patients who would benefit from taxane therapy, though further validation in larger clinical trial populations is required to establish its clinical utility .

What are the molecular mechanisms underlying TLE3's role in chemotherapy response?

The molecular basis for TLE3's association with taxane response involves complex cellular pathways:

• Transcriptional regulation: As a corepressor, TLE3 binds to various transcription factors and modulates gene expression programs that may influence cell survival pathways .

• Wnt signaling inhibition: TLE3 inhibits transcriptional activation mediated by CTNNB1 and TCF family members in Wnt signaling , which may affect cancer cell resistance mechanisms.

• Cell cycle regulation: Taxanes disrupt microtubule dynamics and mitosis. TLE3 may regulate genes involved in these processes, potentially explaining the correlation with treatment response.

• Tumor microenvironment interactions: TLE3-mediated transcriptional programs might influence tumor-stroma interactions relevant to drug penetration and efficacy.

Further mechanistic studies are needed to elucidate the precise molecular pathways through which TLE3 influences taxane sensitivity. Researchers investigating this relationship should consider combining TLE3 expression analysis with functional genomics approaches to identify downstream effectors.

What methodological approaches can improve TLE3 antibody specificity for isoform detection?

Detecting specific TLE3 isoforms requires refined methodological approaches:

• Epitope targeting: Select antibodies raised against immunogens specific to the isoform of interest. For example, antibodies targeting amino acids 150-250 of human TLE3 like ab213596 may recognize specific isoforms.

• Validation techniques:

  • Western blotting with isoform-specific positive controls

  • RNA interference targeting specific isoform transcripts

  • Recombinant expression of individual isoforms for antibody validation

• Preabsorption controls: Test antibody specificity by preincubating with recombinant proteins representing different isoforms.

• Complementary methods: Combine antibody-based detection with RT-PCR or RNA-seq to confirm isoform-specific expression patterns.

• Advanced imaging: Consider super-resolution microscopy to detect subtle differences in subcellular localization between isoforms.

Researchers should systematically document the isoform specificity of TLE3 antibodies and clearly report which isoforms are detected in their experimental systems.

How can deep learning approaches enhance TLE3 antibody development for research applications?

Recent advances in deep learning for antibody design offer promising approaches for developing enhanced TLE3 antibodies:

• Sequence optimization: Deep learning models trained on antibody sequence databases can generate novel antibody sequences with improved specificity and developability attributes .

• Structure prediction: AI-based structural prediction can optimize antibody-antigen interactions specific to TLE3 epitopes.

• Developability screening: Machine learning algorithms can evaluate antibody sequences for properties like expression yield, stability, and non-specific binding .

• Experimental validation efficiency: In silico-generated antibodies with high "medicine-likeness" (>90th percentile) and humanness (>90%) have shown experimental success in expression, monomer content, and thermal stability .

• Application-specific optimization: Models could be trained to generate antibodies optimized for specific applications (IHC vs WB vs IF).

A deep learning approach successfully generated 100,000 variable region sequences of antigen-agnostic human antibodies with favorable biophysical properties and validated 51 diverse candidates experimentally . Similar approaches could potentially be applied to develop novel TLE3-specific antibodies with enhanced research performance.

What are the best practices for quantitative analysis of TLE3 expression in tumor samples?

For rigorous quantitative analysis of TLE3 expression in tumor samples, researchers should implement these methodological best practices:

• Standardized scoring system:

  • Define clear threshold criteria (e.g., >30% nuclear staining)

  • Consider both staining intensity and proportion of positive cells

  • Implement digital pathology for objective quantification

• Technical considerations:

  • Use consistent fixation and processing protocols

  • Include positive and negative controls in each batch

  • Perform replicate staining when possible

  • Account for tumor heterogeneity by evaluating multiple regions

• Statistical approaches:

  • Use appropriate statistical methods for predictive biomarker analysis

  • Apply multiple testing corrections for exploratory studies

  • Validate findings in independent cohorts

• Integration with other biomarkers:

  • Consider TLE3 in the context of established markers

  • Evaluate potential for inclusion in multivariate index assays

  • Correlate with molecular subtypes

• Reporting guidelines:

  • Document antibody clone, dilution, and staining protocol

  • Report inter-observer variability and validation measures

  • Follow REMARK guidelines for biomarker studies

These approaches enhance reproducibility and clinical translation potential of TLE3 expression analysis in cancer research.

What are the optimal conditions for Western blot detection of TLE3 protein?

For optimal Western blot detection of TLE3 protein, the following methodological details are recommended:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Human cell lines such as HEK293 can serve as positive controls

  • Include phosphatase inhibitors if studying TLE3 phosphorylation states

• Electrophoresis parameters:

  • Use gels with appropriate resolution for detecting the 83 kDa TLE3 protein

  • Run molecular weight markers to confirm band identification

• Antibody conditions:

  • Primary antibody: Use anti-TLE3 antibody at a 1:500 dilution for Western blotting

  • Secondary antibody: Select based on host species of primary antibody

  • Blocking: Optimize blocking conditions to minimize background

• Detection and analysis:

  • Use appropriate chemiluminescent or fluorescent detection methods

  • Quantify band intensity using standardized software

  • Normalize to appropriate loading controls

• Troubleshooting strategies:

  • For weak signals: Increase protein loading or antibody concentration

  • For multiple bands: Verify specificity with knockdown controls

  • For high background: Optimize blocking and washing steps

These technical parameters should be optimized for each laboratory's specific experimental conditions.

How can I develop a multiplexed immunofluorescence protocol incorporating TLE3 antibody?

Developing a robust multiplexed immunofluorescence protocol incorporating TLE3 antibody requires careful methodological planning:

• Antibody panel design:

  • Select antibodies from different host species to avoid cross-reactivity

  • Include TLE3 antibody (4 μg/ml concentration has been validated for IF applications)

  • Combine with markers relevant to your research question (e.g., cell type markers, other signaling proteins)

• Sample preparation:

  • PFA-fixation followed by Triton X-100 permeabilization has been validated for TLE3 detection

  • Optimize antigen retrieval conditions for formalin-fixed tissues

• Staining protocol:

  • Sequential staining: Apply antibodies sequentially with washing steps

  • Simultaneous staining: If using antibodies from different species

  • Consider tyramide signal amplification for low-abundance targets

• Imaging considerations:

  • Use appropriate filter sets to distinguish fluorophores

  • Implement spectral unmixing for closely overlapping signals

  • Acquire z-stacks for three-dimensional analysis when necessary

• Controls and validation:

  • Single-color controls to establish signal specificity

  • Fluorescence-minus-one controls to assess bleed-through

  • Biological controls (TLE3-high and TLE3-low samples)

This approach enables simultaneous visualization of TLE3 with other proteins of interest, such as microtubules, which have been successfully co-stained with TLE3 in previous studies .

What quality control steps are essential when using TLE3 antibody for high-throughput screening?

When implementing TLE3 antibody in high-throughput screening applications, incorporate these critical quality control measures:

• Antibody batch validation:

  • Test each new lot against previous lots using reference samples

  • Verify consistent staining patterns and signal-to-noise ratios

  • Document lot-specific optimal concentrations

• Automated staining platform optimization:

  • Validate TLE3 antibody performance on automated systems

  • Implement rigorous temperature and humidity controls

  • Develop standardized protocols with minimal variability

• Positive and negative controls:

  • Include tissue microarray controls in each staining run

  • Use cell lines with known TLE3 expression levels

  • Consider genetically modified controls (knockout/overexpression)

• Statistical quality monitoring:

  • Track staining metrics across batches

  • Implement Westgard rules or similar QC algorithms

  • Establish acceptance criteria for run validity

• Image acquisition standardization:

  • Calibrate imaging systems regularly

  • Use consistent exposure settings

  • Implement automated focusing algorithms

• Data normalization strategies:

  • Develop plate-specific and batch-specific normalization methods

  • Implement appropriate positive and negative controls for data normalization

  • Consider reference standards for quantitative comparisons

These measures ensure data reliability when scaling up TLE3 antibody-based assays for large cohort studies or screening applications.

How should TLE3 antibody results be interpreted in the context of tumor heterogeneity?

Interpreting TLE3 antibody staining in heterogeneous tumors requires sophisticated analytical approaches:

• Spatial heterogeneity assessment:

  • Evaluate multiple tumor regions (center, invasive front, etc.)

  • Consider tissue microarray limitations vs. whole section analysis

  • Document regional variability in TLE3 expression patterns

• Quantification methods:

  • Beyond the 30% nuclear positivity threshold , consider:

  • H-score or Allred scoring systems for combined intensity/proportion

  • Digital image analysis for objective quantification

  • Hot-spot analysis vs. average expression measurement

• Correlation with morphological features:

  • Relate TLE3 expression to histological subtypes

  • Assess relationship with differentiation grade

  • Evaluate association with specific morphological patterns

• Multi-marker integration:

  • Combine TLE3 with markers of proliferation, apoptosis, etc.

  • Consider cellular context (stromal vs. epithelial expression)

  • Implement spatial statistics for pattern recognition

• Clinical interpretation frameworks:

  • Develop decision algorithms incorporating heterogeneity

  • Establish reporting standards addressing variability

  • Consider threshold effects in biomarker-treatment correlations

These approaches acknowledge the complexity of tumor biology and enhance the clinical relevance of TLE3 expression analysis.

How can TLE3 antibody applications extend beyond breast cancer to other malignancies?

While TLE3 has been primarily studied in breast cancer, its research applications can be extended to other malignancies through systematic methodological approaches:

• Cross-cancer expression profiling:

  • Conduct TLE3 immunohistochemical analysis across tumor types

  • Correlate expression with molecular subtypes in each cancer

  • Investigate prognostic significance in different malignancies

• Treatment response associations:

  • Evaluate TLE3 as a predictive biomarker for taxane therapy in ovarian, lung, and prostate cancers

  • Investigate relationships with other microtubule-targeting agents

  • Assess correlation with response to targeted therapies

• Pathway analysis integration:

  • Examine TLE3's role in Wnt signaling across cancer types

  • Investigate cancer-specific transcriptional programs regulated by TLE3

  • Study interaction with lineage-specific transcription factors

• Methodological adaptations:

  • Optimize staining protocols for different tissue types

  • Develop cancer-specific scoring systems

  • Validate antibody performance in relevant preclinical models

• Multi-omics integration:

  • Correlate protein expression with genomic alterations

  • Investigate epigenetic regulation of TLE3 expression

  • Combine with transcriptomic data for pathway analysis

These approaches would expand our understanding of TLE3's role beyond breast cancer and potentially identify new clinical applications for TLE3 antibody-based diagnostics.

What new methodologies are emerging for studying TLE3 protein interactions?

Cutting-edge methodologies for investigating TLE3 protein interactions include:

• Proximity-based labeling techniques:

  • BioID or TurboID fusion proteins to identify TLE3 interactors

  • APEX2-based approaches for temporal interaction mapping

  • Split-BioID to study context-specific interactions

• Advanced microscopy approaches:

  • FRET/FLIM to study direct protein interactions in living cells

  • Super-resolution microscopy for spatial organization analysis

  • Live-cell imaging with optogenetic control of TLE3 activity

• Mass spectrometry innovations:

  • Crosslinking mass spectrometry to capture transient interactions

  • Thermal proteome profiling to assess drug effects on TLE3 complexes

  • Quantitative interactomics across cellular conditions

• Microfluidic approaches:

  • Single-cell protein interaction analysis

  • Droplet-based assays for high-throughput screening

  • Organ-on-chip models for tissue-specific interactions

• Computational prediction and validation:

  • Deep learning models for interaction prediction

  • Molecular dynamics simulations of TLE3 complexes

  • Network analysis to identify key interaction hubs

These methods enable researchers to move beyond static understanding of TLE3 function toward dynamic, context-specific interaction mapping with greater relevance to disease biology.

How does post-translational modification affect TLE3 antibody epitope recognition?

Post-translational modifications (PTMs) can significantly impact TLE3 antibody epitope recognition, requiring careful experimental consideration:

• Common TLE3 modifications:

  • Phosphorylation at regulatory sites

  • SUMOylation affecting protein interactions

  • Potential ubiquitination controlling protein turnover

  • O-GlcNAcylation in response to metabolic conditions

• Epitope accessibility considerations:

  • PTMs may directly mask antibody binding sites

  • Conformational changes induced by PTMs can alter epitope exposure

  • Different fixation methods may preserve or destroy modification-dependent epitopes

• Modification-specific detection strategies:

  • Phospho-specific antibodies for studying TLE3 activation states

  • Pretreatment with phosphatases to assess phosphorylation dependence

  • Comparison of multiple antibodies targeting different epitopes

• Experimental design recommendations:

  • Document fixation and preprocessing methods thoroughly

  • Consider treating samples with deubiquitinases or phosphatases

  • Use complementary methods (mass spectrometry) to validate PTM status

• Context-dependent interpretation:

  • Cellular stress may alter PTM patterns

  • Treatment with taxanes or other drugs may affect TLE3 modification

  • Disease states may feature abnormal PTM profiles

Understanding these factors is essential for accurate interpretation of TLE3 antibody results, particularly when comparing data across different experimental conditions or disease states.

What are the emerging applications of TLE3 antibody in cancer immunotherapy research?

TLE3 antibody applications in cancer immunotherapy research represent an emerging frontier:

• Tumor microenvironment characterization:

  • Multiplex TLE3 with immune cell markers to study spatial relationships

  • Investigate TLE3 expression in tumor-infiltrating lymphocytes

  • Assess correlation between TLE3 expression and immunosuppressive features

• Predictive biomarker development:

  • Evaluate TLE3 as a potential biomarker for immunotherapy response

  • Investigate association with immune checkpoint expression

  • Study correlation with tumor mutational burden or neoantigen load

• Mechanistic investigations:

  • Examine TLE3's role in regulating immunomodulatory gene expression

  • Investigate impact on antigen presentation pathways

  • Study effects on cytokine signaling in tumor and immune cells

• Therapeutic targeting strategies:

  • Explore TLE3 inhibition as a method to enhance immunotherapy

  • Investigate combination approaches with taxanes and immunotherapies

  • Develop TLE3-targeted antibody-drug conjugates

• Single-cell analysis applications:

  • Implement TLE3 antibody in mass cytometry (CyTOF) panels

  • Develop protocols for single-cell proteomics including TLE3

  • Combine with transcriptomics for multi-omic characterization

These emerging applications could significantly expand our understanding of TLE3's role in tumor-immune interactions and potentially identify new therapeutic strategies.

How can researchers integrate TLE3 antibody data with other -omics datasets?

Integrating TLE3 antibody data with multi-omics datasets requires sophisticated analytical approaches:

• Data integration frameworks:

  • Implement multi-modal data fusion algorithms

  • Apply dimension reduction techniques to identify patterns across platforms

  • Develop patient-specific integrated profiles

• Correlation with genomic features:

  • Analyze TLE3 expression in relation to copy number alterations

  • Investigate association with specific mutations or mutational signatures

  • Study relationship with chromosomal instability metrics

• Transcriptomic correlations:

  • Identify gene expression signatures associated with TLE3 protein levels

  • Perform gene set enrichment analysis on TLE3-correlated genes

  • Investigate alternative splicing patterns affecting TLE3 function

• Epigenomic integration:

  • Correlate TLE3 protein expression with promoter methylation

  • Analyze histone modifications at TLE3 regulatory regions

  • Study chromatin accessibility in TLE3 target genes

• Clinical data incorporation:

  • Develop integrative predictive models combining TLE3 with omics features

  • Identify multi-omic signatures with treatment response prediction

  • Perform survival analysis using integrated biomarker panels

• Visualization and interpretation tools:

  • Implement multi-omics visualization platforms

  • Develop network-based approaches to interpret integrated data

  • Create interactive dashboards for hypothesis generation

These integrative approaches enhance the biological interpretation of TLE3 expression patterns and improve the translational relevance of research findings.